Trials / Completed
CompletedNCT05164536
Plasma P-tau2017 and Quantitative Amyloid PET Imaging
Plasma P-tau2017 and Quantitative Amyloid PET Imaging in a Cognitively Normal Population
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 140 (actual)
- Sponsor
- Invicro · Academic / Other
- Sex
- All
- Age
- 70 Years
- Healthy volunteers
- Accepted
Summary
The overall goal of this protocol is to compare amyloid burden assessed by amyloid PET to plasma P-tau217 levels.
Detailed description
The overall goal of this protocol is to compare amyloid burden assessed by amyloid PET to plasma P-tau217 levels. Other relevant AD-related investigational biomarkers may also be assessed in the provided samples. Apolipoprotein E (ApoE) genetic status will be evaluated with a serum sample.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amyvid | All participants will undergo a single β-amyloid PET scan with Amyvid. |
Timeline
- Start date
- 2021-08-27
- Primary completion
- 2022-11-08
- Completion
- 2022-11-08
- First posted
- 2021-12-20
- Last updated
- 2025-02-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05164536. Inclusion in this directory is not an endorsement.